Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mechanism of claudin-2 in RTECs apoptosis after renal obstruction.

Urolithiasis·2026

Same author

Pancreatic Metastasis from Intracranial Solitary Fibrous Tumor/Hemangiopericytoma Mimicking a Pancreatic Neuroendocrine Tumor: A Case Report and Focused Literature Review.

Current oncology (Toronto, Ont.)·2026

Same author

Explaining rural-urban disparities in child stunting in African least developed countries: a multi-country cross-sectional analysis.

International journal for equity in health·2026

Same author

Apoptosis, Pyroptosis, and Necroptosis (PANoptosis) may be Present in Renal Ischemic Injury.

Current medicinal chemistry·2026

Same author

Advances in Nanozyme Engineering for Precision Oral Health Management.

International dental journal·2026

Same author

Targeted Protein Degradation and Delivery Strategies in the Context of Neurological Disorders.

ACS nano·2026

Search research articles

Related Experiment Video

Updated: Jul 8, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

Improving antibody optimization ability of generative adversarial network through large language model.

Wenbin Zhao¹, Xiaowei Luo¹, Fan Tong¹

¹Academy of Military Medical Sciences, Beijing 100850, China.

Computational and Structural Biotechnology Journal

|December 11, 2023

Summary

This summary is machine-generated.

We developed AbGAN-LMG, a new generative adversarial network (GAN) that uses language models to create high-quality antibody sequences. This approach improves antibody optimization and generates diverse, developable antibodies with higher binding affinity for SARS-CoV-2.

Keywords:

Antibody optimization Generative Adversarial Network Language model

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Related Experiment Videos

Last Updated: Jul 8, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Area of Science:

Computational Biology
Immunoinformatics
Artificial Intelligence in Drug Discovery

Background:

Generative adversarial networks (GANs) can create functional protein sequences but often lack specificity, hindering the identification of desirable antibodies.
Optimizing antibodies computationally is crucial due to the high cost of experimental validation, yet enhancing GANs for generating high-quality candidates remains a challenge.

Purpose of the Study:

To introduce and evaluate the Language Model Guided Antibody Generative Adversarial Network (AbGAN-LMG) for improved antibody sequence generation.
To leverage language models' representational power to enhance GANs' ability to produce high-quality, developable antibody candidates.

Main Methods:

Developed AbGAN-LMG, a novel GAN architecture incorporating a language model as an input.
Evaluated AbGAN-LMG's performance by generating antibody libraries and sequences for SARS-CoV-2 and MERS-CoV.
Assessed sequence quality, library diversity, developability, and binding affinity via molecular docking.

Main Results:

AbGAN-LMG successfully learned fundamental antibody characteristics and increased the diversity of generated antibody libraries.
Over 50% of generated antibody sequences targeting AZD-8895 exhibited superior developability compared to the original antibody.
Identified 70 candidate antibodies with higher binding affinity to the SARS-CoV-2 receptor-binding domain (RBD) than AZD-8895.

Conclusions:

Integrating language models with GANs, as demonstrated by AbGAN-LMG, significantly enhances the generation of high-quality antibody libraries and candidate sequences.
AbGAN-LMG improves the efficiency of antibody optimization, offering a promising computational tool for antibody discovery and development.
The AbGAN-LMG model is publicly available for further research and application in antibody engineering.